猫犬主要过敏原蛋白的最新研究进展

doi:10.11843/j.issn.0366-6964.2024.02.006

摘要/Abstract

摘要： 猫犬过敏原可引发症状严重程度不一的过敏反应,诱发人类鼻炎和哮喘等,危害严重。在犬猫的皮屑、毛发、唾液、舌下腺等提取物中发现有多种致敏原。在很多公共场所(如医院、学校、办公室等)检测到的过敏原浓度足以引发过敏性疾病或者使症状加重,这些症状困扰着爱猫犬人士。目前,针对猫犬过敏最有效的治疗方法依然是过敏原特异性免疫疗法。本综述主要对当前犬猫过敏原的种类、异源表达、治疗方法的研究进展进行总结,并对过敏制剂的应用进行了展望,这为解决犬猫过敏症这一难题提供了新的思路。

关键词: 猫过敏原, 犬过敏原, 特异性免疫治疗, 疫苗, 重组过敏原

Abstract: The cat and dog allergens can cause rhinitis, asthma, and other allergic reactions. A variety of allergens have been found in the extracts from pet dander, hair, saliva, and sublingual glands. The concentrations of allergens detected in many public buildings without pets (such as hospitals, schools, offices, etc.) are sufficient to cause or exacerbate allergic diseases in people. At present, allergen-specific immunotherapy is the most effective treatment for feline and canine allergy. This review mainly summarized the current research progress in the treatment of cat and dog allergens and the application of anti-allergic drugs. It provides a novel idea for the prevention and control of feline and canine allergy.

Key words: cat allergens, dog allergens, specific immunotherapy, vaccines, recombinant allergen

中图分类号:

李春晓, 安尉, 高博泉, 王振龙, 韩冰, 陶慧, 王金全, 王秀敏. 猫犬主要过敏原蛋白的最新研究进展[J]. 畜牧兽医学报, 2024, 55(2): 471-480.

LI Chunxiao, AN Wei, GAO Boquan, WANG Zhenlong, HAN Bing, TAO Hui, WANG Jinquan, WANG Xiumin. Recent Progress of Major Allergens in Cats and Dogs[J]. Acta Veterinaria et Zootechnica Sinica, 2024, 55(2): 471-480.

参考文献

[1] KONRADSEN J R, FUJISAWA T, VAN HAGE M, et al. Allergy to furry animals:new insights, diagnostic approaches, and challenges[J]. J Allergy Clin Immunol, 2015, 135(3):616-625.
[2] ANDERSON M C, BAER H. Allergenically active components of cat allergen extracts[J]. J Immunol, 1981, 127(3):972-975.
[3] HEINZERLING L M, BURBACH G J, EDENHARTER G, et al. GA²LEN skin test study I:GA²LEN harmonization of skin prick testing:novel sensitization patterns for inhalant allergens in Europe[J]. Allergy, 2009, 64(10):1498-1506.
[4] DÁVILA I, DOMÍNGUEZ-ORTEGA J, NAVARRO-PULIDO A, et al. Consensus document on dog and cat allergy[J]. Allergy, 2018, 73(6):1206-1222.
[5] 邱晨, 薛仁杰, 田曼. 宠物过敏原与儿童气道过敏性疾病的关系[J]. 医学综述, 2019, 25(13):2520-2524.
QIU C, XUE R J, TIAN M. Relationship between pet allergens and airway allergic diseases in children[J]. Medical Recapitulate, 2019, 25(13):2520-2524.(in Chinese)
[6] MORRIS D O. Human allergy to environmental pet danders:a public health perspective[J]. Vet Dermatol, 2010, 21(5):441-449.
[7] KAISER L, GRÖNLUND H, SANDALOVA T, et al. The crystal structure of the major cat allergen Fel d 1, a member of the secretoglobin family[J]. J Biol Chem, 2003, 278(39):37730-37735.
[8] BONNET B, MESSAOUDI K, JACOMET F, et al. An update on molecular cat allergens:Fel d 1 and what else? Chapter 1:Fel d 1, the major cat allergen[J]. Allergy Asthma Clin Immunol, 2018, 14:14.
[9] CHARPIN C, MATA P, CHARPIN D, et al. Fel d I allergen distribution in cat fur and skin[J]. J Allergy Clin Immunol, 1991, 88(1):77-82.
[10] KAISER L, VELICKOVIC T C, BADIA-MARTINEZ D, et al. Structural characterization of the tetrameric form of the major cat allergen Fel d 1[J]. J Mol Biol, 2007, 370(4):714-727.
[11] ICHIKAWA K, VAILES L D, POMÉS A, et al. Identification of a novel cat allergen-cystatin[J]. Int Arch Allergy Immunol, 2001, 124(1-3):55-56.
[12] UKLEJA-SOKOŁOWSKA N, GAWRON ȘKA-UKLEJA E, ŻBIKOWSKA-GOTZ M, et al. Analysis of feline and canine allergen components in patients sensitized to pets[J]. Allergy Asthma Clin Immunol, 2016, 12:61.
[13] TSOLAKIS N, MALINOVSCHI A, NORDVALL L, et al. Sensitization to minor cat allergen components is associated with type-2 biomarkers in young asthmatics[J]. Clin Exp Allergy, 2018, 48(9):1186-1194.
[14] EMARA M, ROYER P J, ABBAS Z, et al. Recognition of the major cat allergen Fel d 1 through the cysteine-rich domain of the mannose receptor determines its allergenicity[J]. J Biol Chem, 2011, 286(15):13033-13040.
[15] SATYARAJ E, WEDNER H J, BOUSQUET J. Keep the cat, change the care pathway:a transformational approach to managing Fel d 1, the major cat allergen[J]. Allergy, 2019, 74(S107):5-17.
[16] SPARKES A H. Human allergy to cats:a review for veterinarians on prevalence, causes, symptoms and control[J]. J Feline Med Surg, 2022, 24(1):31-42.
[17] GLASGOW B J, ABDURAGIMOV A R, GASYMOV O K, et al. Tear lipocalin:structure, function and molecular mechanisms of action[M]//SULLIVAN D A, STERN M E, TSUBOTA K, et al. Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3:Basic Science and Clinical Relevance Part B. New York:Springer, 2002:555-565.
[18] REDL B. Human tear lipocalin[J]. Biochim Biophys Acta, 2000, 1482(1-2):241-248.
[19] HABELER M, REDL B. Phage-display reveals interaction of lipocalin allergen Can f 1 with a peptide resembling the antigen binding region of a human γδT-cell receptor[J]. Biol Chem, 2020, 402(4):433-437.
[20] SMALLWOOD J, OWNBY D. Exposure to dog allergens and subsequent allergic sensitization:an updated review[J]. Curr Allergy Asthma Rep, 2012, 12(5):424-428.
[21] MIN J, FOO A C Y, GABEL S A, et al. Structural and ligand binding analysis of the pet allergens Can f 1 and Fel f 7[J/OL]. Front Allergy, 2023, 4:1133412.[2024-01-25] https://www.frontiersin.org/articles/10.3389/falgy.2023.1133412/full.
[22] MATTSSON L, LUNDGREN T, EVERBERG H, et al. Prostatic kallikrein:a new major dog allergen[J]. J Allergy Clin Immunol, 2009, 123(2):362-368. e3.
[23] NIEMI M H, RYTKÖNEN-NISSINEN M, JÄNIS J, et al. Structural aspects of dog allergies:the crystal structure of a dog dander allergen Can f 4[J]. Mol Immunol, 2014, 61(1):7-15.
[24] SMITH D M, COOP C A. Dog allergen immunotherapy:past, present, and future[J]. Ann Allergy Asthma Immunol, 2016, 116(3):188-193.
[25] WINTERSAND A, ASPLUND K, BINNMYR J, et al. Allergens in dog extracts:implication for diagnosis and treatment[J]. Allergy, 2019, 74(8):1472-1479.
[26] KHURANA T, NEWMAN-LINDSAY S, YOUNG P R, et al. The NPC2 protein:a novel dog allergen[J]. Ann Allergy Asthma Immunol, 2016, 116(5):440-446. e2.
[27] CALZADA D, ARANDA T, ALLEGO G M, et al. Immunological mechanisms involved in the human response to a dog dander allergoid[J]. Mol Immunol, 2022, 145:88-96.
[28] SCHOU C, SVENDSEN U G, LΦWENSTEIN H. Purification and characterization of the major dog allergen, Can f I[J]. Clin Exp Allergy, 1991, 21(3):321-328.
[29] NILSSON O B, BINNMYR J, ZOLTOWSKA A, et al. Characterization of the dog lipocalin allergen Can f 6:the role in cross-reactivity with cat and horse[J]. Allergy, 2012, 67(6):751-757.
[30] 高莹, 李淼, 孙元, 等. 乳酸乳球菌表达系统的发展现状与前景展望[J]. 微生物学报, 2022, 62(3):895-905.
GAO Y, LI M, SUN Y, et al. Development and prospects of Lactococcus lactis expression system[J]. Acta Microbiologica Sinica, 2022, 62(3):895-905.(in Chinese)
[31] WELLS E, ROBINSON A S. Cellular engineering for therapeutic protein production:product quality, host modification, and process improvement[J]. Biotechnol J, 2017, 12(1):1600105.
[32] BUDGE J D, KNIGHT T J, POVEY J, et al. Engineering of Chinese hamster ovary cell lipid metabolism results in an expanded ER and enhanced recombinant biotherapeutic protein production[J]. Metab Eng, 2020, 57:203-216.
[33] NARAYAN G, AGRAWAL A, JOSHI N, et al. Protein production and purification of a codon-optimized human NGN3 transcription factor from E.coli[J]. Protein J, 2021, 40(6):891-906.
[34] 朱明慧, 李晓静, 王浩民, 等. 原核和真核双表达载体的构建及功能分析[J]. 中国细胞生物学学报, 2022, 44(3):437-442.
ZHU M H, LI X J, WANG H M, et al. Construction and functional analysis of prokaryotic and eukaryotic dual expression vectors[J]. Chinese Journal of Cell Biology, 2022, 44(3):437-442.(in Chinese)
[35] 裴业春, 安晓荣, 侯健, 等. 猫重组变应原Fel d 1与乙肝病毒核心抗原融合基因的原核表达[J]. 中国畜牧兽医, 2016, 43(11):2826-2833.
PEI Y C, AN X R, HOU J, et al. Prokaryotic expression of fusion gene of cat recombinant Allergen Fel d 1 with hepatitis B core antigen[J]. China Animal Husbandry & Veterinary Medicine, 2016, 43(11):2826-2833.(in Chinese)
[36] SCHMITZ N, DIETMEIER K, BAUER M, et al. Displaying Fel d 1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity:a novel therapy for cat allergy[J]. J Exp Med, 2009, 206(9):1941-1955.
[37] CURIN M, WEBER M, THALHAMER T, et al. Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction[J]. Clin Exp Allergy, 2014, 44(6):882-894.
[38] 周婕. 猫过敏原重组蛋白突变体的构建及免疫学鉴定[D]. 广州:广州医学院, 2012.
ZHOU J. Construction and immunological identification of cat allergen recombinant protein mutants[D]. Guangzhou:Guangzhou Medical University, 2012.(in Chinese)
[39] 许卓谦, 刘志刚. 猫过敏原Fel d 1基因的克隆、表达及特性鉴定[J]. 中华微生物学和免疫学杂志, 2006, 26(12):1037.
XU Z Q, LIU Z G. Cloning, expression and characterization of feline allergen Fel d 1[J]. Chinese Journal of Microbiology and Immunology, 2006, 26(12):1037.(in Chinese)
[40] GRÖNLUND H, BERGMAN T, SANDSTRÖM K, et al. Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli[J]. J Biol Chem, 2003, 278(14):40144-40151.
[41] DURHAM S R, WALKER S M, VARGA E M, et al. Long-term clinical efficacy of grass-pollen immunotherapy[J]. N Engl J Med, 1999, 341(7):468-475.
[42] MIRONE C, ALBERT F, TOSI A, et al. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen:a double-blind, placebo-controlled study[J]. Clin Exp Allergy, 2004, 34(9):1408-1414.
[43] CHAN S K, LEUNG D Y M. Dog and cat allergies:current state of diagnostic approaches and challenges[J]. Allergy Asthma Immunol Res, 2018, 10(2):97-105.
[44] PFAAR O, SAGER A, ROBINSON D S. Safety and effect on reported symptoms of depigmented polymerized allergen immunotherapy:a retrospective study of 2927 paediatric patients[J]. Pediatr Allergy Immunol, 2015, 26(3):280-286.
[45] ALVAREZ-CUESTA E, CUESTA-HERRANZ J, PUYANA-RUIZ J, et al. Monoclonal antibody-standardized cat extract immunotherapy:risk-benefit effects from a double-blind placebo study[J]. J Allergy Clin Immunol, 1994, 93(3):556-566.
[46] EWBANK P A, MURRAY J, SANDERS K, et al. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract[J]. J Allergy Clin Immunol, 2003, 111(1):155-161.
[47] MELLERUP M T, HAHN G W, POULSEN L K, et al. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment[J]. Clin Exp Allergy, 2000, 30(10):1423-1429.
[48] MORALES M, GALLEGO M, IRAOLA V, et al. In vitro evidence of efficacy and safety of a polymerized cat dander extract for allergen immunotherapy[J]. BMC Immunol, 2017, 18(1):10.
[49] CHIRUMBOLO S, BJΦRKLUND G, SBOARINA A, et al. The role of basophils as innate immune regulatory cells in allergy and immunotherapy[J]. Hum Vaccin Immunother, 2018, 14(4):815-831.
[50] CHAPMAN M D, SMITH A M, VAILES L D, et al. Recombinant allergens for diagnosis and therapy of allergic disease[J]. J Allergy Clin Immunol, 2000, 106(3):409-418.
[51] LUZAR J, MOLEK P, ŠILAR M, et al. Identification and characterization of major cat allergen Fel d 1 mimotopes on filamentous phage carriers[J]. Mol Immunol, 2016, 71:176-183.
[52] THOMS F, JENNINGS G T, MAUDRICH M, et al. Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects[J]. J Allergy Clin Immunol, 2019, 144(1):193-203.
[53] 裴业春. DNA疫苗和蛋白疫苗共免疫防治猫过敏症及其作用机理研究[M]. 北京:中国农业科学技术出版社, 2017.
PEI Y C. Study on that co-immunization of DNA vaccine and protein vaccine against cat allergy and its mechanism[M]. Beijing:China Agricultural Science and Technology Press, 2017.(in Chinese)
[54] NAKATSUJI M, SUGIURA K, SUDA K, et al. Structure-based prediction of the IgE epitopes of the major dog allergen Can f 1[J]. FEBS J, 2022, 289(6):1668-1679.
[55] IMMONEN A, FARCI S, TAIVAINEN A, et al. T cell epitope-containing peptides of the major dog allergen Can f 1 as candidates for allergen immunotherapy[J]. J Immunol, 2005, 175(6):3614-3620.
[56] JUNTUNEN R, LIUKKO A, TAIVAINEN A, et al. Suboptimal recognition of a T cell epitope of the major dog allergen Can f 1 by human T cells[J]. Mol Immunol, 2009, 46(16):3320-3327.
[57] CARLANDER D, KOLLBERG H, WEJÅKER P E, et al. Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections[J]. Immunol Res, 2000, 21(1):1-6.
[58] AKBARI M R, AHMADI A, MIRKALANTARI S, et al. Anti-Vibrio cholerae IgY antibody inhibits mortality in suckling mice model[J]. J Natl Med Assoc, 2018, 110(1):84-87.
[59] 周继萍, 曹瑞敏, 米克热木·沙依布扎提, 等. 猪硒蛋白W的原核表达及IgY多克隆抗体制备[J]. 中国畜牧兽医, 2019, 46(6):1801-1807.
ZHOU J P, CAO R M, MIKEREMU S, et al. Prokaryotic expression of porcine selenoprotein W and preparation of IgY polyclonal antibody[J]. China Animal Husbandry & Veterinary Medicine, 2019, 46(6):1801-1807.(in Chinese)
[60] 段海龙, 余晓东, 邓骛远, 等. 抗白唇竹叶青蛇毒卵黄抗体(IgY)的制备及其稳定性研究[J]. 现代预防医学, 2014, 41(6):1074-1077.
DUAN H L, YU X D, DENG W Y, et al. Study on the development of antibody (IgY) against Trimeresurus albolabris venom from Hen Egg Yolk and its physicochemical stability[J]. Modern Preventive Medicine, 2014, 41(6):1074-1077.(in Chinese)
[61] ARTMAN C, IDEGWU N, BRUMFIELD K D, et al. Feasibility of polyclonal avian immunoglobulins (IgY) as prophylaxis against human norovirus infection[J]. Viruses, 2022, 14(11):2371.
[62] CARRARA G M P, SILVA G B, FARIA L S, et al. IgY antibody and human neurocysticercosis:a novel approach on immunodiagnosis using Taenia crassiceps[LL]hydrophobic antigens[J]. Parasitology, 2020, 147(2):240-247.
[63] HAN S J, WEN Y, YANG F F, et al. Chicken egg yolk antibody (IgY) protects mice against enterotoxigenic Escherichia coli infection through improving intestinal health and immune response[J]. Front Cell Infect Microbiol, 2021, 11:662710.
[64] 王飞, 张禾, 等. 卵黄抗体对鸽毛滴虫与白色念珠菌感染的治疗效果[J]. 畜牧兽医学报, 2022, 53(2):658-662.
WANG F, ZHANG H, CAI Y H, et al. The therapeutic effect of yolk antibody on the infection of Trichomonas gallinae and Candida albicans[J]. Acta Veterinaria et Zootechnica Sinica, 2022, 53(2):658-662.(in Chinese)
[65] SATYARAJ E, SUN P C, SHERRILL S. Fel d1 Blocking antibodies:a novel method to reduce IgE-mediated allergy to cats[J]. J Immunol Res, 2021, 2021:5545173.
[66] SATYARAJ E, GARDNER C, FILIPI I, et al. Reduction of active Fel d1 from cats using an antiFel d1 egg IgY antibody[J]. Immun Inflamm Dis, 2019, 7(2):68-73.
[67] HEDLIN G, GRAFF-LONNEVIG V, HEILBORN H, et al. Immunotherapy with cat-and dog-dander extracts. V. Effects of 3 years of treatment[J]. J Allergy Clin Immunol, 1991, 87(5):955-964.
[68] LILJA G, SUNDIN B, GRAFF-LONNEVIG V, et al. Immunotherapy with cat-and dog-dander extracts. IV. Effects of 2 years of treatment[J]. J Allergy Clin Immunol, 1989, 83(1):37-44.